申请人:ASCENTAGE PHARMA (SUZHOU) CO., LTD.
公开号:US20210340158A1
公开(公告)日:2021-11-04
Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R
8
, R
9a
, R
9b
, R
9c
, R
9d
, X, Y, Z, Z
1
, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.